Trial Profile
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Sep 2023 Results published in the Oncologist
- 28 Jul 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.